Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma
- PMID: 17917309
- DOI: 10.1507/endocrj.k07-059
Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma
Abstract
Silent corticotroph adenoma (SCA) is defined as an ACTH-producing pituitary tumor not associated with clinical and endocrine feartures of Cushing's syndrome, but its underlying molecular mechanism(s) remains unknown thus far. We tested the hypothesis that reduced expression of prohormone convertase (PC) 1/3 responsible for proteolytic processing of proopiomelanocortin (POMC) in SCA may lead to production of unprocessed, biologically inactive POMC and/or precursor of ACTH. Among 30 non-functioning pituitary macroadenomas (NFA) examined, we found 6 SCAs by immunohistochemical study using anti-ACTH antibody. Preoperative endocrine and diagnostic image tests did not reveal any differences between SCA and the remaining NFA except for the higher recurrence rate of SCA. While steady-state PC1/3 mRNA levels determined by RT-PCR were almost comparable between SCAs and NFAs, immunohistochemical study showed negative immunostaining for PC1/3 in all 6 SCAs. Our data suggest that defective PC1/3 expression may lead to preferential production of unprocessed, biologically inactive ACTH variants in SCA.
Similar articles
-
Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.Eur J Endocrinol. 2010 Jul;163(1):35-43. doi: 10.1530/EJE-10-0076. Epub 2010 Apr 12. Eur J Endocrinol. 2010. PMID: 20385723
-
PCSK1N as a Tumor Size Marker and an ER Stress Response Protein in Corticotroph Pituitary Adenomas.J Clin Endocrinol Metab. 2025 Mar 17;110(4):1065-1075. doi: 10.1210/clinem/dgae643. J Clin Endocrinol Metab. 2025. PMID: 39288010 Free PMC article.
-
Differential gene expression in ACTH -secreting and non-functioning pituitary tumors.Eur J Endocrinol. 2007 Dec;157(6):717-24. doi: 10.1530/EJE-07-0428. Eur J Endocrinol. 2007. PMID: 18057378
-
Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.Pituitary. 2018 Feb;21(1):32-40. doi: 10.1007/s11102-017-0844-4. Pituitary. 2018. PMID: 29032459
-
Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].Endocr J. 2014;61(10):941-8. doi: 10.1507/endocrj.ej14-0120. Epub 2014 Jun 29. Endocr J. 2014. PMID: 24974880 Review.
Cited by
-
Recent advances in understanding corticotroph pituitary tumor initiation and progression.F1000Res. 2018 Aug 29;7:F1000 Faculty Rev-1354. doi: 10.12688/f1000research.14789.1. eCollection 2018. F1000Res. 2018. PMID: 30228864 Free PMC article. Review.
-
An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.Cancers (Basel). 2021 Dec 6;13(23):6134. doi: 10.3390/cancers13236134. Cancers (Basel). 2021. PMID: 34885244 Free PMC article. Review.
-
Postoperative expression of Cushing disease in a young male: metamorphosis of silent corticotroph adenoma?Endocrinol Diabetes Metab Case Rep. 2019 Oct 1;2019:19-0046. doi: 10.1530/EDM-19-0046. Online ahead of print. Endocrinol Diabetes Metab Case Rep. 2019. PMID: 31671410 Free PMC article.
-
The diverging role of O-GlcNAc transferase in corticotroph and somatotroph adenomas.Pituitary. 2024 Oct;27(5):577-589. doi: 10.1007/s11102-024-01431-x. Epub 2024 Jul 27. Pituitary. 2024. PMID: 39066842 Free PMC article.
-
Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing's disease harbouring microadenomas or macroadenomas.J Endocrinol Invest. 2016 Dec;39(12):1401-1409. doi: 10.1007/s40618-016-0504-y. Epub 2016 Jun 30. J Endocrinol Invest. 2016. PMID: 27363699
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous